A phase I and pharmacokinetic study of ganetespib (STA-9090) in advanced hepatocellular carcinoma
详细信息    查看全文
  • 作者：Lipika Goyal (1) (3)
    Raymond C. Wadlow (4)
    Lawrence S. Blaszkowsky (1) (3)
    Brian M. Wolpin (2) (3)
    Thomas A. Abrams (2) (3)
    Nadine Jackson McCleary (2) (3)
    Susan Sheehan (1)
    Eamala Sundaram (1)
    Michael D. Karol (5)
    John Chen (5)
    Andrew X. Zhu (1) (3)
  • 关键词：Hepatocellular carcinoma ; STA ; 9090 ; Ganetespib ; Phase I ; Heat shock protein inhibitors ; Pharmacokinetics ; Hepatic dysfunction
  • 刊名：Investigational New Drugs
  • 出版年：2015
  • 出版时间：February 2015
  • 年：2015
  • 卷：33
  • 期：1
  • 页码：128-137
  • 全文大小：278 KB
  • 参考文献：1. Ferlay, J., GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase [Internet]. International Agency for Research on Cancer: Lyon, <country-region鈥?gt;鈥?lt;/country-region鈥?gt;鈥塅rance, 2010; Vol. No. 10
    2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, H盲ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378鈥?0 CrossRef
    3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z (2009) Efficacy and safety of sorafenib in patients in the Asia-pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25鈥?4 CrossRef
    4. Qin S, Bai Y, Ye S, Al E (2010) Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin as palliative systemic chemotherapy in advanced HCC in Asian patients. J Clin Oncol 28
    5. Gish RG, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Jeziorski K, Leighton J, Gallo J, Kennealey GT (2007) Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 25:3069鈥?5 CrossRef
    6. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:479鈥?3 CrossRef
    7. Cheng A (2011) Phase III trial of sunitinib (Su) versus Sorafenib (So) in advanced hepatocellular carcinoma (HCC). In 2011 ASCO Annual Meeting, J Clin Oncol Vol. 29
    8. Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Avi帽a J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL (2013) Brivanib versus Sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31:3517鈥?4 CrossRef
    9. Cainap C, Qin S, Huang W-T, Chung IJ, Pan H, Cheng Y, Kudo M, Kang YK, Chen PJ, Toh HC, Gorbunova V, Eskens F, Qian J, McKee MD, Ricker JL, Carlson DM, El Nowiem S (2012) Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 30: (suppl 34; abstr 249)
    10. Zhu AX, RO, Evans J, et al (2012) SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with hepatocellular carcinoma (HCC). In 37th Annual European Society for Medical Oncology Congress, Vienna, Austria
    11. Izzo, C., Ramucirumab Misses Primary Endpoint in Phase III HCC Trial. 2014
    12. Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW (2013) Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom Sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31:3509鈥?6 CrossRef
    13. Zhu AX, Kudo M, Assenat E, Cattan S, Kang Y-K, Lim HY, Poon RTP, Blanc J-F, Vogel A, Chen C-L, Dorval E, Peck-Radsavljevic M, Santoro A, Daniele B, Furuse J, Jappe A, Perraud KP, Anak O, Sellami DB, Chen L-T (2014) In EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after Sorafenib. Gastrointestinal Cancers Symposium, San Francisco, CA, JCO, San Francisco
    14. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537鈥?9 CrossRef
    15. Whitesell L, Lindquist SL (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5:761鈥?2 CrossRef
    16. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J Biol Chem 271:22796鈥?01 CrossRef
    17. Schneider C, Sepp-Lorenzino L, Nimmesgern E, Ouerfelli O, Danishefsky S, Rosen N, Hartl FU (1996) Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc Natl Acad Sci U S A 93:14536鈥?1 CrossRef
    18. Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F (2005) Role of HSP90, CDC37, and CRM1 as modulators of P16 (INK4A) activity in rat liver carcinogenesis and human liver cancer. Hepatology 42:1310鈥? CrossRef
    19. Lee CL, Hsiao HH, Lin CW, Wu SP, Huang SY, Wu CY, Wang AH, Khoo KH (2003) Strategic shotgun proteomics approach for efficient construction of an expression map of targeted protein families in hepatoma cell lines. Proteomics 3:2472鈥?6 mic.200300586" target="_blank" title="It opens in new window">CrossRef
    20. Leng AM, Liu T, Yang J, Cui JF, Li XH, Zhu YN, Xiong T, Zhang G, Chen Y (2012) The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells. Cell Biol Int 36:893鈥? CrossRef
    21. Wang, X.; Wang, S.; Liu, Y.; Ding, W.; Zheng, K.; Xiang, Y.; Liu, K.; Wang, D.; Zeng, Y.; Xia, M.; Yang, D.; Wang, Y., The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: The role of ER stress. Biochem Biophys Res Commun 2014.
    22. Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, Zhou D, Inoue T, Tatsuta N, Sang J, Ye S, Acquaviva J, Ogawa LS, Wada Y, Barsoum J, Koya K (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11:475鈥?4 CrossRef
    23. Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA (2013) Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 3:430鈥?3 CrossRef
    24. Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Leiblich, C. W.; Fasano, J.; Moynahan, M. E.; D鈥橝ndrea, G.; Lim, K.; Reddington, L.; Haque, S.; Patil, S.; Bauman, L.; Vukovic, V.; El-Hariry, I.; Hudis, C.; Modi, S., A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer. Clin Breast Cancer 2013
    25. Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI (2013) A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 19:3068鈥?7 CrossRef
    26. Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS (2013) A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer 13:152 CrossRef
    27. Llovet JM, Burroughs A, Bruix J (2003) Hepatocellular carcinoma. Lancet 362:1907鈥?7 CrossRef
    28. Patel H, Egorin MJ, Remick SC, Mulkerin D, Takimoto CHM, Doroshow JH, Potter D, Ivy SP, Murgo AJ, Ramanathan RK (2004) Comparison of child-Pugh (CP) criteria and NCI organ dysfunction working group (NCI-ODWG) criteria for hepatic dysfunction (HD): implications for chemotherapy dosing. In J Clin Oncol 22:14s, (suppl;abst 6051), 2004
    29. Supko JG, Hickman RL, Grever MR, Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305鈥?5 CrossRef
    30. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, Burrows F, Storgard C, Von Hoff D (2013) Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 71:1345鈥?5 CrossRef
    31. Strassburg CP, Kalthoff S, Ehmer U (2008) Variability and function of family 1 uridine-5鈥?diphosphate glucuronosyltransferases (UGT1A). Crit Rev Clin Lab Sci 45:485鈥?30 CrossRef
    32. Acquaviva, J.; He, S.; Zhang, C.; Jimenez, J. P.; Nagai, M.; Sang, J.; Sequeira, M.; Smith, D. L.; Shin Ogawa, L.; Inoue, T.; Tatsuta, N.; Knowles, M. A.; Bates, R. C.; Proia, D. A., FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism. Mol Cancer Res 2014
    33. Strassburg CP, Oldhafer K, Manns MP, Tukey RH (1997) Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol 52:212鈥?0
    34. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 425:407鈥?0 CrossRef
    35. Ramalingam, S., GD; Andric, Z.; Bondarenko, I.; Zaric, B.; Ceric, T.; al., e., A randomized study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel versus docetaxel alone for second-line therapy of lung adenocarcinoma (GALAXY-1). In ASCO, J Clin Oncol 31, s.; CRA8007), a., Eds. Chicago, 2013
    36. Guo, W.; Yan, L.; Yang, L.; Liu, X.; E, Q.; Gao, P.; Ye, X.; Liu, W.; Zuo, J., Targeting GRP75 Improves HSP90 Inhibitor Efficacy by Enhancing p53-Mediated Apoptosis in Hepatocellular Carcinoma. PLoS One 2014, 9, e85766
    37. Chen Y, Chen J, Loo A, Jaeger S, Bagdasarian L, Yu J, Chung F, Korn J, Ruddy D, Guo R, McLaughlin ME, Feng F, Zhu P, Stegmeier F, Pagliarini R, Porter D, Zhou W (2013) Targeting HSF1 sensitizes cancer cells to HSP90 inhibition. Oncotarget 4:816鈥?9
  • 作者单位：Lipika Goyal (1) (3)
    Raymond C. Wadlow (4)
    Lawrence S. Blaszkowsky (1) (3)
    Brian M. Wolpin (2) (3)
    Thomas A. Abrams (2) (3)
    Nadine Jackson McCleary (2) (3)
    Susan Sheehan (1)
    Eamala Sundaram (1)
    Michael D. Karol (5)
    John Chen (5)
    Andrew X. Zhu (1) (3)

    1. Massachusetts General Hospital Cancer Center, 55 Fruit Street, LH/PB 220, Boston, MA, 02114, USA
    3. Harvard Medical School, Boston, MA, USA
    4. Virginia Cancer Specialists, Fairfax, VA, USA
    2. Dana Farber Cancer Institute, Boston, MA, USA
    5. Synta Pharmaceuticals Corp, Lexington, MA, USA
  • 刊物类别：Medicine
  • 刊物主题：Medicine & Public Health
    Oncology
    Pharmacology and Toxicology
  • 出版者：Springer Netherlands
  • ISSN：1573-0646
文摘
NGLC 2004-2010.National Geological Library of China All Rights Reserved.
Add:29 Xueyuan Rd,Haidian District,Beijing,PRC. Mail Add: 8324 mailbox 100083
For exchange or info please contact us via email.